Equities

Quanterix Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
QTRX:NMQ

Quanterix Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)5.74
  • Today's Change-0.150 / -2.55%
  • Shares traded279.75k
  • 1 Year change-28.78%
  • Beta1.0756
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Quanterix Corporation is engaged in fueling scientific discovery through ultra-sensitive biomarker detection. The Company’s Simoa technology delivers earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the level of quantification (LoQ). Its precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Its products and services include Simoa Assay Kits, Simoa Dry Blood Extraction Kit, LDTs & Assay Services, Instruments, Simoa Accelerator Laboratory, Homebrew-Custom Assay Development, and Nova Beads. LDTs & Assay Services include Simoa p-Tau 217, Simoa NfL LDT, and LucentAD pTau 217. Its instruments include Simoa HD-X Analyzer-Automated Immunoassays, Quanterix SR-X Biomarker Detection System, and SP-X Imaging and Analysis System.

  • Revenue in USD (TTM)130.20m
  • Net income in USD-95.66m
  • Incorporated2007
  • Employees471.00
  • Location
    Quanterix Corp900 Middlesex TurnpikeBILLERICA 01821United StatesUSA
  • Phone+1 (302) 658-7581
  • Fax+1 (302) 655-5049
  • Websitehttps://www.quanterix.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Orchestra Biomed Holdings Inc2.82m-75.10m216.26m70.00--4.94--76.74-1.82-1.820.06760.77460.03130.657833.7540,257.14-83.39---104.85--93.01---2,665.05--4.72--0.2451---4.42---24.23------
KORU Medical Systems Inc39.07m-3.71m216.33m80.00--13.13--5.54-0.0807-0.08070.84820.35571.433.537.39488,383.00-13.62-19.85-18.41-23.1662.3259.62-9.50-24.861.92--0.0335--17.987.7555.85--25.82--
CapsoVision Inc13.09m-22.56m226.25m----11.06--17.29-0.4873-0.48730.28260.4368----------------53.13---172.37--4.50--0.00--20.54---76.01------
908 Devices Inc57.64m-57.10m234.89m246.00--1.72--4.08-1.61-0.11161.623.770.31231.764.17234,296.80-30.94-18.01-37.82-19.6749.3552.89-99.07-78.453.12--0.00--18.7227.11-98.37--8.96--
Simulations Plus Inc78.68m-64.25m247.60m212.00--1.95--3.15-3.20-3.203.906.310.4701--4.28371,113.20-38.39-2.50-40.84-2.6559.6069.96-81.66-7.29----0.00--13.0913.74-750.17--7.57-24.21
Applied Energetics Inc1.15m-13.02m256.97m21.00------222.85-0.0599-0.05990.0053-0.00330.3065--7.7054,908.57-345.27-139.08-454.84-208.3658.5860.61-1,126.59-473.16---------7.78---24.71--51.42--
Quanterix Corp130.20m-95.66m268.12m471.00--0.8519--2.06-2.33-2.333.216.740.30451.444.06276,439.50-22.37-13.18-25.81-14.5351.5356.14-73.47-45.092.31--0.0029--12.3019.36-35.89---20.86--
Shoulder Innovations Inc41.63m-34.45m269.06m61.00--1.82--6.46-1.91-1.912.247.18----------------76.67---82.75--9.80--0.0913--64.07---50.85------
Sight Sciences Inc76.05m-46.11m283.39m216.00--4.37--3.73-0.8955-0.89551.471.230.58541.426.71352,092.60-35.49-35.50-39.37-38.5386.8382.63-60.63-94.208.93-76.380.384---1.4727.897.27---10.54--
Carlsmed Inc-100.00bn-100.00bn291.19m100.00--2.73----------4.01------------------------11.91--0.1265--97.16---31.49------
Trubridge Inc349.88m5.42m292.68m3.20k52.571.629.130.83650.37090.370924.2312.020.8737257.086.17109,338.401.39-0.91071.60-1.0353.1650.131.59-1.141.902.400.4768--0.9464.5256.05--61.10--
Owlet Inc99.64m-42.45m301.46m80.00------3.03-2.75-2.756.08-2.341.523.804.361,245,500.00-60.37-64.44-244.32-331.1152.0644.29-39.68-58.720.9074-2.48----44.529.4054.08---17.23--
Senseonics Holdings Inc29.30m-63.77m306.85m117.00--3.92--10.47-1.65-1.650.75651.920.2483.625.22250,410.30-53.98-71.11-70.98-94.7541.11-14.81-217.65-594.095.93-29.180.3109--0.36621.08-30.18--16.46--
Evolent Health Inc2.05bn-180.89m311.37m4.50k--0.3697--0.1516-1.57-1.5717.857.550.829--5.17456,456.00-5.17-5.93-6.41-8.0018.4221.07-6.24-7.16--0.1890.5572--30.0930.0434.31---6.87--
Data as of Feb 13 2026. Currency figures normalised to Quanterix Corp's reporting currency: US Dollar USD

Institutional shareholders

44.54%Per cent of shares held by top holders
HolderShares% Held
Portolan Capital Management LLCas of 30 Sep 20254.26m9.17%
Threadneedle Asset Management Ltd.as of 30 Sep 20253.14m6.75%
BlackRock Fund Advisorsas of 31 Dec 20253.08m6.64%
The Vanguard Group, Inc.as of 31 Dec 20252.39m5.14%
William Blair Investment Management LLCas of 31 Dec 20252.05m4.40%
Invenomic Capital Management LPas of 30 Sep 20251.39m3.00%
Millennium Management LLCas of 30 Sep 20251.21m2.60%
Columbia Management Investment Advisers LLCas of 30 Sep 20251.11m2.38%
Geode Capital Management LLCas of 31 Dec 20251.07m2.31%
Kent Lake PR LLCas of 30 Sep 20251.00m2.15%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.